Viking Therapeutics to present two posters on its VK2735 program at the 33rd European Congress on Obesity
Viking Therapeutics announced that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.
At ECO, Viking will present a poster highlighting data from its Phase 2 VENTURE-Oral Dosing trial, focusing on key efficacy and safety endpoints, including weight loss and tolerability during the 13-week study. The second poster will highlight the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity.
Details of the ECO poster presentations are as follows:
Title: Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding VENTURE-Oral Study
Publication Number: PO4.260
Presented by: Karen Modesto, M.D., Vice President, Clinical Development
Date/Time: On display May 12-15, with poster networking session on Thursday, May 14, from 18:00 – 19:15 Turkey Time
Location: Poster area at Level B5, Istanbul Congress Center
Title: VANQUISH-1: Phase 3 Trial With Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight with Weight Related Comorbidities
Publication Number: PO4.278
Presented by: Karen Modesto, M.D., Vice President, Clinical Development
Date/Time: On display May 12-15, with poster networking session on Thursday, May 14, from 18:00 – 19:15 Turkey Time
Location: Poster area at Level B5, Istanbul Congress Center
